



**GUJARAT THEMIS BIOSYN LIMITED**  
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

(Rs. in lacs)

**PART I : Statement of Unaudited Financial Results for the Quarter ended 30th June, 2013**

Particulars	Three Months Ended			Year Ended 31-03-2013 (Audited)
	30-06-2013 (Unaudited)	31-03-2013 (Unaudited)	30-06-2012 (Unaudited)	
1. Income from operations (a) Net sales/income from operations (Net of excise duty) (b) Other operating income	769.62 0.77 770.39	732.09 0.49 732.58	635.02 1.47 636.49	2,832.63 4.03 2,836.66
2. Total income from operations (net) Expenses (a) Cost of raw materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (e) Depreciation and amortisation expense (f) Impairment of fixed assets (g) Other expenses (i) Stores & Spares (ii) Power (iii) Fuel (iv) Water (v) Other Expenditure	96.80 36.57 7.29 - - 106.94 36.83 62.69 46.09 284.52 117.42 10.07 70.90	106.94 36.83 12.34 - - 106.94 36.83 62.69 49.91 274.17 111.74 9.47 65.35	80.03 29.39 50.83 38.10 25.21 80.03 29.39 - 30.85 204.48 121.19 38.26 50.75	360.74 142.46 81.87 38.10 25.20 360.74 142.46 62.69 177.52 995.22 514.80 38.26 241.15
3. Total expenses Profit / (Loss) from operations before other income, finance costs and exceptional items (1 - 2)	669.66 100.73	729.43 3.14	640.08 (3.60)	2,678.02 158.63
4. Other income	2.04	7.43	12.73	26.20
5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	102.77	10.58	9.13	184.83
6. Finance costs	17.99	15.15	23.23	77.85
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	84.78	(4.58)	(14.10)	106.98
8. Exceptional items	-	-	-	-
9. Net Profit from ordinary activities before tax (7 + 8)	84.78	(4.58)	(14.10)	106.98
10. Tax expense	-	-	-	-
11. Net Profit from ordinary activities after tax (9 - 10)	84.78	(4.58)	(14.10)	106.98
12. Extraordinary items (net of tax expense)	-	-	-	-
13. Net Profit for the period (11 + 12)	84.78	(4.58)	(14.10)	106.98
14. Paid-up equity share capital Face Value Rs.5/- per share each	726.40	726.40	726.40	726.40
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(1,712.99)
16.i Earnings per share (before extraordinary items) Face Value Rs.5/- per share each (not annualised): (a) Basic (b) Diluted	0.58 0.58	(0.03) (0.03)	(0.11) (0.11)	0.75 0.75
16.ii Earnings per share (after extraordinary items) Face Value Rs.5/- per share each (not annualised): (a) Basic (b) Diluted	0.58 0.58	(0.03) (0.03)	(0.11) (0.11)	0.75 0.75

**PART II : Select information for the Quarter ended 30th June, 2013**

A PARTICULARS OF SHAREHOLDING	30-06-2013 (Unaudited)	31-03-2013 (Unaudited)	30-06-2012 (Unaudited)	31-03-2013 (Audited)
1. Public shareholding - Number of shares - Percentage of shareholding	2,209,957 15.21%	2,209,957 15.21%	2,209,957 15.21%	2,209,957 15.21%
2. Promoters and Promoter Group Shareholding a) Pledged / Encumbered b) Non - Encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 12,318,745 100.00% 84.79%	Nil 12,318,745 100.00% 84.79%	Nil 12,318,745 100.00% 84.79%	Nil 12,318,745 100.00% 84.79%

B PARTICULARS	Quarter ended 30-06-2013
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil





**Notes:**

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at its their respective meeting held on 12th August, 2013
- 2 The Company is manufacturing Bulk Drugs for its own and on job work basis for others. Hence, there is no separate reportable segment as per Accounting Standard - 17 (AS-17) "Segment Reporting" by as notified by Companies (Accounting Standards) Rules 2006.
- 3 The figures for the previous quarter ended 31st March, 2013 are balancing figures between the audited figures in respect of the full financial year ended 31st March 2013 and published year to date figures upto the third quarter of the financial year 2012-2013.
- 4 In view of carry forward losses/ unabsorbed depreciation of earlier years , no provision for the Income Tax has been made.
- 5 In respect of Auditor's qualifications / observations in the Audit Report for the year ended 31<sup>st</sup> March, 2013 that:
  - a) Some of the balances of trade payable, trade receivables, deposits, loans & advances and liability for expenses are subject to confirmation and adjustments necessary upon reconciliation if any, consequential impact thereof in the financial statements is not ascertainable.' The Mangement does not expect any material variation in the financial statements.
  - b) Preparation of accounts on the basis of a going concern inspite of negative net worth and working capital deficiency. The company has initiated efforts including development of new products and has also ventured into manufacture of goods on own and on job work basis so as to reduce the losses. The Company has made profit for the quater ended 30th June'2013, previous year ended 31st March 2013 and 31st March 2012. Futher the Rehabilitation Scheme has been sanctioned by the Board for Industrial and Financial Reconstruction (BIFR) in the hearing held 12th January, 2012. Accordingly these accounts have been prepared on a going concern basis.
  - c) Regarding non-maintenance of the proper records showing the full particulars including quantitative details and situation of Fixed Assets and in the absence of physical verification during the year discrepancies between book records and physical availability could not be ascertained. The management is of the view that there will be no material discrepancies between Fixed Assets records as per books and its physical availability.
- 6 The figures of previous period / year have been regrouped / rearranged wherever necessary / practicable to conform to current period / year presentation.

By order of the Board of Directors  
For GUJARAT THEMIS BIOSYN LTD.

Dr. DHVESH PATEL  
Chairman

Place : Mumbai  
Date : 12th August 2013

